Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: Semiquantitative drug susceptibility testing and genotyping

Journal of Clinical Microbiology

Volumn 46, Issue 12, 2008, Pages 4064-4067

  Springer, Burkhard ^a,b,c   Calligaris Maibach, Romana C ^a,b   Ritter, Claudia ^a,b   Böttger, Erik C ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Nationales Zentrum fur Mykobakterien   (Switzerland)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ETHAMBUTOL; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ARTICLE; DRUG SENSITIVITY; GENOTYPE; IN VITRO STUDY; ISOLATION PROCEDURE; LABORATORY TEST; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SAMPLE SIZE; SAMPLING; SPECIES ENDEMICITY; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; GENOTYPE; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 57349120030     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01114-08     Document Type: Article

References (20)

1. Böttger, E. C. 2001. Drug-resistant tuberculosis. Lancet 357:1288-1289.
2. Böttger, E. C., B. Springer, M. Pletschette, and P. Sander. 1998. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat. Med. 4:1343-1344.
3. Böttger, E. C., and B. Springer. 2008. Tuberculosis: drug resistance, fitness, and strategies for global control. Eur. J. Pediatr. 67:141-148.
4. CDC. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55:301-305.
5. Cynamon, M. H., Y. Zhang, T. Harpster, S. Cheng, and M. S. DeStefano. 1999. High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection. Antimicrob. Agents Chemother. 43:2922-2924.
6. Espinal, M. A., S. I. Kim, G. Suarez, K. M. Kam, A. G. Khomenko, G. B. Migliori, J. Baéz, A. Kochi, C. Dye, and M. C. Ravligione. 2000. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283:2537-2545.
7. Finken, M., P. Kirschner, A. Meier, A. Wrede, and E. C. Böttger. 1993. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNS pseudoknot. Mol. Microbiol. 9:1239-1246.
8. Hillemann, D., S. Rüsch-Gerdes, and E. Richter. 2007. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 45:2635-2640.
9. Jayaram, R., R. K. Shandil, S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, E. Kantharaj, and V. Balasubramanian. 2004. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 48:2951-2957.
10. Johnson, R., A. M. Jordaan, L. Pretorius, E. Engelke, G. van der Spuy, M. Bosman, P. D. van Helden, R. Warren, and T. C. Victor. 2006. Ethambutol resistance testing by mutation detection. Int. J. Tuberc. Lung Dis. 10:68-73.
11. Kim, H. R., S. S. Hwang, H. J. Kim, S. M. Lee, C. G. Yoo, Y. W. Kim, S. K. Han, Y. S. Shim, and J. J. Yim. 2007. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin. Infect. Dis. 45:1290-1295.
12. Kim, S. J. 2005. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur. Respir. J. 25:564-569.
13. Larsen, M. H., C. Vilchèze, L. Kremer, G. S. Basra, L. Parsons, M. Salfinger, L. Heifets, M. H. Hazbon, D. Alland, J. C. Sacchettini, and W. R. Jacobs, Jr. 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol. Microbiol. 46:453-466.
14. Madison, B., B. Robinson-Dunn, I. George, W. Gross, H. Lipman, B. Metchuck, A. Sloctsky, G. Washabange, G. Mazurek, and J. Riddershof. 2002. Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J. Clin. Microbiol. 40:3976-3979.
15. Meier, A., P. Sander, K. J. Schaper, M. Scholz, and E. C. Böttger. 1996. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:2452-2454.
16. Miotto, P., F. Piana, D. M. Cirillo, and G. B. Migliori. 2008. Genotype MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 46:393-394.
17. Nuernberger, E., and J. Grosset. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur. J. Clin. Microbiol. Infect. Dis. 23:243-255.
18. Prammananan, T., P. Sander, B. A. Brown, K. Frischkorn, G. O. Onyi, Y. Zhang, E. C. Böttger, and R. J. Wallace, Jr. 1998. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J. Infect. Dis. 177:1573-1581.
19. Sander, P., B. Springer, T. Prammananan, A. Sturmfels, M. Kappler, M. Pletschette, and E. C. Böttger. 2002. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob. Agents Chemother. 46:1204-1211.
20. van Soolingen, D., P. E. de Haas, H. R. van Doorn, E. Kuijper, H. Rinder, and M. W. Borgdorff. 2000. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J. Infect. Dis. 182:1788-1790.